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I. Introduction 
 
Hyperadrenocorticism (HAC) in dogs is caused either by a cortisol secreting adrenal 
tumour or a pituitary adenoma secreting high doses of adrenocorticotropic hormone 
(ACTH) which then stimulates the adrenal glands to produce high amounts of 
cortisol. The chronic excess of systemic cortisol results in multiple clinical signs of 
various organ systems. 
Numerous medical and surgical treatments have been established. Adrenalectomy is 
the treatment of choice for adrenal tumours. Hypophysectomy is the best treatment 
option for pituitary-dependent  HAC, however, this technique is not widely available. 
Thus, the emphasis in managing pituitary-dependent HAC is on pharmacollogical 
treatment. The most commonly used drug is mitotane, but various others have been 
tried, including ketoconazole, L-deprenyl and aminoglutethimide. However, because 
of variable efficacy and side effects none of them is entirely satisfactory.  
Since the late 1990ies trilostane, a competitive and reversible inhibitor of the 3ß-
hydroxysteroid dehydrogenase, has been used for the treatment of canine HAC. So 
far, the experiences with trilostane are promising. Unfortunately, no pharmacological 
data in dogs with HAC are available and possible alterations in serum electrolyte 
concentrations as well as steroid hormone levels throughout the day are still 
unknown.  
This study investigated the use of trilostane for the treatment of canine pituitary-
dependent HAC and its effects on serum sodium, potassium and calcium, 
endogenous ACTH, cortisol, renin and aldosterone. The serum concentrations of 
trilostane and ketotrilostane were also determined. Blood samples were collected 
over 24 hours once HAC had been satisfactorily controlled. 
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II. Literature Review 
 
1. Hyperadrenocorticism in Dogs 
 
Next to hypothyroidism, HAC is the most common endocrine disorder in dogs (47).  
 
Spontaneous HAC is most frequently caused by an ACTH-secreting pituitary tumour. 
This form is usually termed pituitary-dependent hyperadrenocorticism (PDH). Only 
about 15 to 20% of dogs with spontaneous HAC have an adrenocortical tumour (AT) 
which can equally be an adenoma or adenocarcinoma (47).  
 
Most symptoms of HAC are not the direct results of the tumour, although the 
expansion of a pituitary macroadenoma may cause seizures and other signs of the 
central nervous system; local or distant metastases of an adrenal adenocarcinoma 
may cause further unspecific clinical signs. More often, however, an increase of 
circulating glucocorticoids affecting multiple organ systems is the main reason for 
various signs of illness. Since these symptoms are not the subject of this study, for 
detailed information see Feldman and Nelson (2005) (17). 
 
Once signalement, history and clinical examination lead to the suspicion of HAC, 
blood and urine should be analyzed. Typical results are a stress leucogram 
(neutrophilia, lymphopaenia, monocytosis and eosinophilia), high serum cholesterol 
and asymmetrically high values of alkaline phosphatase with moderate increases of 
other hepatic enzymes. The urinalysis may show isosthenuria or hyposthenuria. Signs 
of complications, such as glucosuria in connection with hyperglycaemia or a lower 
urinary tract infection may also be seen (48). Proteinuria is rather common in dogs 
with HAC even if signs of lower urinary tract infection are missing (29). 
 
To ultimately confirm the diagnosis of HAC, more specific tests are necessary. The 
ACTH stimulation test, the low dose dexamethasone suppression test and the urine 
corticoid/creatinine-ratio are routinely used screening tests. The ACTH stimulation 
test demonstrates the reaction of cortisol release after administration of 
supraphysiological doses of ACTH. The low dose dexamethasone suppression test, on 
the other hand, demonstrates the suppression of cortisol levels after application of 
dexamethasone, which inhibits by feed-back mechanism the release of endogenous 
ACTH. Both tests have in common that they are acceptably sensitive but less specific. 
Because of its high sensitivity and its low specificity, a negative result of the urine 
corticoid/creatinine-ratio can quite securely rule out HAC, but it is not qualified to 
make the diagnosis (33). Unfortunately, dogs with severe non-adrenal diseases may 
show positive test results in all three screening tests due to chronic stimulation of the 
hypothalamus-hypophysis-adrenal gland axis (33). 
 
Several possibilities exist to differentiate between PDH and AT, the two best being to 
analyse both adrenal glands ultrasonographically (3,24) or to measure plasma 
endogenous ACTH (61,72). Because of these newer possibilities, the high dose 
dexamethasone suppression test is mainly indicated if neither the possibility to 
perform ultrasound nor to measure endogenous ACTH is given (47). 
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2. Treatment of hyperadrenocorticism in dogs 
 
Microsurgical transsphenoidal hypophysectomy is an effective method of treating 
PDH (40) because it erases both the clinical signs caused by the excessive secretion 
of glucocorticoids and eventually occurring central nervous symptoms caused by the 
expansion of the tumour. Nevertheless, it requires considerable surgical expertise, 
represents a risky procedure and is not widely available. While radiotherapy reduces 
the size of pituitary tumours, it does not result in adequate control of clinical signs of 
HAC (21). Therefore, most dogs with PDH are still treated pharmacollogically.  
In contrast, hormone-producing adrenal masses may be surgically removed. 
Nevertheless, some owners decide against surgery mainly because of the advanced 
age of their dog or due to the risk and the financial constraints.  
 
Mitotane (o,p’-DDD) is the drug most commonly used for the treatment of HAC. It 
causes progressive necrosis of the adrenal cortex. Although it selectively destroys the 
glucocorticoid-producing zona fasciculata, the production of mineralcorticoids from 
the zona glomerulosa may become affected as well, with the risk of developing 
hypoadrenocorticism. In a study including 200 dogs with PDH treated with mitotane 
(55), approximately 30% of the dogs showed adverse effects such as lethargy, 
anorexia, neurological dysfunction, vomiting or diarrhoea. Eleven of the patients 
developed signs of glucocorticoid/mineralcorticoid deficiency and 2 died as a result of 
an Addisonian crisis. In 53.5% of the dogs, relapses were common at least once in 
the course of therapy. In addition, its adrenolytic effect is potentially harmful to the 
owners who handle the drug regularly. Mitotane can be used to treat both AT as well 
as PDH. 
 
Several other medical treatments for HAC have been tried, all with variable success, 
side effects and cost.  
 
Ketoconazole, an imidazole derivative commonly given as an antifungal agent, 
inhibits cytochrome P450-dependent enzymes. It specifically reduces serum cortisol 
levels whilst sparing the aldosterone synthesis (36). 20% to 25% of the dogs in one 
study did not respond to ketoconazole (15). The hepatotoxic potential also limits its 
use. 
 
Another drug tried to treat canine HAC is selegeline hydrochloride or l-deprenyl. 
Regularly used to treat Parkinson’s disease in humans, it represents a selective and 
irreversible inhibitor of monoamine oxidase type B. Thus, serum concentration of 
dopamine increases which causes a decrease of endogenous ACTH and thereby a 
decrease of serum cortisol. Although the drug is safe for pet and owner, only 10% to 
20% of the dogs treated showed clinical improvement (7,59). This is not unexpected 
since selegeline mainly has an effect on the intermediate part of the pituitary gland 
while canine PDH mainly derives from the pars distalis. 
 
In 2002 aminoglutethimide was evaluated as an alternative therapy to mitotane. It 
inhibits the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby 
suppressing steroidogenesis. In high doses, it inhibits 11ß-hydroxylase and reduces 
cortisol, aldosterone and adrenal sex hormone production (56). Perez et al. (56) 
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found it to be inefficient at reducing cortisol levels. It also showed marked 
hepatotoxicity and can therefore not be recommended. 
 
2a. Trilostane 
 
Pharmacology 
Trilostane is a synthetic, orally active steroid analogue. It acts as a competitive 
inhibitor of the 3ß-hydroxysteroid dehydrogenase enzyme system and thereby 
inhibits the synthesis of several steroid hormones, including cortisol and aldosterone. 
This blockage is reversible and seems to be dose-related (57). Because of this block, 
an accumulation of steroid hormone precursors above the site of the enzymatic 
inhibition can be found (66). 
 
Pharmacologic data on trilostane uptake and release are available on rats (1,57,39), 
monkeys (1) and humans (60) and show quite marked differences amongst these 
species. In healthy beagle dogs trilostane is rapidly absorbed after oral application 
with peak blood concentrations found within 1.5 hours. Trilostane plasma levels 
decrease to baseline values in about 18 hours. There is quite a variation of plasma 
trilostane levels in these dogs, possibly in part due to the low water solubility of 
trilostane and thus erratic absorption from the gastrointestinal tract (data on file – 
Arnolds Ltd). 
 
In vivo, trilostane and its metabolite ketotrilostane seem to be present in a state of 
equilibrium. Once trilostane is given orally, ketotrilostane develops rapidly. 
Correspondingly, if ketotrilostane is given to rats, trilostane is formed within a few 
minutes (39). Ketotrilostane shows 1.7-times the activity of trilostane in the inhibition 
of steroidogenesis (60).  
 
After metabolism of trilostane into one of 4 additional metabolites, trilostane and 
ketotrilostane are either excreted mainly via faeces, as found in rats, or mainly via 
urine, as found in monkeys (1). So far the excretory pathway in dogs is unknown. 
 11
Figure 1: Major biosynthetic pathways of adrenocortical steroid biosynthesis.  
The final end products are in bold. The asterix indicates the enzyme 3ß-hydroxysteroid 
dehydrogenase wich is blocked by trilostane. 
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Use in humans 
Trilostane was originally developed for human medicine. Although most cases of HAC 
in humans are treated surgically, several studies have examined the use of trilostane 
in the treatment of inoperable or already metastasized tumours. Indications to use 
trilostane in humans are incomplete remission after surgery or the need of a 
symptomatic therapy before surgery in patients in serious conditions like 
hypertension or diabetes mellitus (62). 
 
First experiences of 6 patients with HAC treated with trilostane were published by 
Komanicky et al. in 1978 (34). They concluded that trilostane was an effective drug 
with minimal side effects and satisfactory improvement in clinical and biochemical 
parameters. However, more recent work has cast some doubt on these conclusions. 
While in one study, half of the patients responded to therapy (65), in another study 
the 7 patients treated with trilostane showed neither a consistent fall of serum 
cortisol levels nor a rise in steroid precursors (12). These observations suggest that 
trilostane is not useful in the treatment of human HAC. 
 
Whilst the results in treating human HAC are not satisfying, various studies show that 
it is useful in the treatment of both primary (43,50,72) and secondary 
hyperaldosteronism (23). 
 
Imbalances of sex hormones, especially a postmenopausal increase of oestrone, are 
discussed to trigger human breast cancer (53). Since trilostane also shows some 
effect on the biosynthesis of sex hormones, it may be used in chemotherapy 
protocols of postmenopausal breast cancer. Beardwell et al. (4) showed that 
androstendione, 17-hydroxyprogesterone, pro-gesterone, testosterone and oestradiol 
decrease during trilostane therapy while oestrone increases. Several studies showed 
some success of trilostane in breast cancer therapy (10,30,72). The outcome was 
best after previous hormonal therapy (30). Chu et al. found a complete remission in 
4% and a partial response in 19% of the patients (10). In contrast, Coombs et al. 
concluded that trilostane is not useful in human breast cancer. Gaining information 
from 41 patients with advanced breast cancer, only one responded to therapy and in 
six patients the condition stabilized with the remaining failing to respond (11). 
 
Regardless of the reason for trilostane treatment, mostly gastrointestinal adverse 
effect were noted, ranging from slight, self-limiting diarrhoea (23,73), abdominal 
discomfort, light-headedness (30), facial flushing, oral paraesthesia and nausea (10) 
to fierce diarrhoea, abdominal cramping (10) and leucopaenia (30). One case report 
deals with an Addisonian crisis caused by trilostane (70). Because of its effect on 
male sex hormone biosyntheses, Semple et al. point to the possibility of sexual 
dysfunction during trilostane therapy (65). 
 
Use in canine pituitary-dependent hyperadrenocorticism  
The first positive experiences with trilostane in dogs with PDH were published in 
abstract format in 1998 (28). Since then, there have been several controlled studies 
(5,41,45,61) showing that trilostane can be used effectively and safely for the 
treatment of canine PDH. 
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Published in 2002 (45), a study of 78 dogs with PDH arrived at the conclusion that 
trilostane was effective and well tolerated by almost all dogs. Only two dogs showed 
signs of hypoadrenocorticism and two dogs died of unknown cause shortly after 
starting treatment. There was a significant reduction of both the mean basal and 
post-ACTH cortisol concentrations after a mean of 12.3 days of treatment. Polyuria 
and polydipsia resolved in 70% of the dogs presented with these problems and the 
skin of 62% of the dogs with dermatological changes normalized due to therapy. The 
dogs were treated and documented for up to three years. 
 
In the same year data on clinical improvement and laboratory testing of 11 dogs with 
PDH treated with trilostane showed similar results (61). In addition, changes in the 
ultrasonographic appearance of the adrenal glands were noted in the course of 
therapy (37). This confirmed what Ruckstuhl et al. had described earlier (61). They 
found that trilostane causes enlargement of the adrenal glands with a maximum size 
achieved at about 6 weeks after initiation of treatment and minor fluctuations of size 
thereafter. Furthermore, there were noticeable changes within the parenchyma: The 
differentiation between the two layers of the glands (cortex and medulla) became 
more apparent, attributable to an increase of the hypoechoic outer zone and a 
decrease in the hyperechoic centre. After long-time treatment, the shape of the 
adrenal glands was irregular and the parenchyma had a heterogeneous echogenity. 
It appears that these changes reflect nodular hyperplasia as a morphologic 
consequence of long-standing hypersecretion of ACTH. The authors state that it 
cannot be ruled out that these changes may represent some kind of pre-cancerosis.  
 
Successful treatment in 29 of 30 dogs with PDH was also reported by Braddock et al. 
(5). 
 
A further study of 60 dogs (42 dogs with PDH, 11 with AT and 7 unclassified) 
investigated mainly satisfaction of owners and improvement of clinical and laboratory 
parameters over a period of 6 months (41). It found significant decreases in serum 
cholesterol, serum alkaline phosphatase and alanine transaminase levels. However, 
28 of the 60 patients still had alkaline phosphatase levels above the reference range 
at the end of the study. Furthermore, there was a significant increase of serum 
potassium while the serum sodium levels decreased significantly. On 24 occasions, a 
sodium-potassium-ratio of less than 24 was found. However, hyperkalaemia was 
never treated in any of these incidences. While mild, self-limiting side effects such as 
diarrhoea, vomiting and lethargy were noted by 63% of owners mainly at the 
beginning of therapy, overall improvement of clinical signs was seen in 83% of the 
patients. 
 
Including all 4 studies mentioned above, the mean starting dose was about 6 mg/kg 
once daily (5,41,45,61). More than 50% of the patients needed a dose adjustment, 
mainly a dose increase. Most dogs were initially quite sensitive to the drug for 10 to 
30 days and then required a higher dose. This resulted in a final dose of 6.1 to 11.4 
mg/kg in three of the studies (41,45,61). Since Braddock et al. (5) aimed at a 
markedly lower post-ACTH cortisol concentration, there was a much higher mean 
final dose of 18.1 mg/kg documented. The highest dose given to a dog was 48.7 
mg/kg without side effects. Some of the dogs treated for more than 2 years required 
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reduction or temporary cessation of trilostane; the reason why these animals became 
more sensitive is unknown (5). 
 
In a recent study performed by Sieber-Ruckstuhl et al. (66) several hormones such 
as cortisol, aldosterone, androgen, endogenous ACTH and steroid precursors both 
located before and after the 3ß-hydroxysteroid dehydrogenase were measured 
before and at two time points after starting treatment with trilostane. Some of the 
results were as expected, but others did differ from what was expected. Most 
important was that levels of steroid precursors localised below the 3ß-steroid 
dehydrogenase enzyme system were unchanged or even increased. This suggests 
strongly that trilostane inhibits not only the 3ß-steroid dehydrogenase – as already 
known (57) – but also other enzymes, most likely the 11ß-hydroxylase and possibly 
the 11ß-hydroxysteroid dehydrogenase (66). Further studies have to show whether 
these interpretations are true. 
 
Hypoadrenocorticoid signs 
In human beings, one case of an Addisonian crisis under trilostane therapy was 
described (70). 
In the four studies mentioned above (5,41,45,61), 180 dogs with PDH were treated 
with trilostane. Only 2 dogs showed signs of hypoadrenocorticism. None of them died 
because of an Addisonian crisis, but two dogs participating in one study died of 
unknown cause (45). Melville-Walker et al. (41) found 24 occasions with 
sodium/potassium-ratios of less than 24, but none of the patients showed signs of 
hypoadrenocorticism. Eastwood et al. (14) describe five cases of prolonged 
hypoadrenocorticism under trilostane treatment. The patients showed extreme 
lethargy, weakness and poor appetite; low basal cortisol concentrations and a lack of 
response to exogenous ACTH were documented. Hypoadrenocorticism lasted up to 4 
months. Where the patients did not fully recover, trilostane induced adrenal necrosis 
was considered possible. 
Chapman et al. (8) observed clinical and biochemical changes suggestive of 
hypoadrenocorticism in a dog shortly after beginning therapy with trilostane. A 
histopathological analysis after exploratory laparotomy and excisional biopsy revealed 
adrenal cortical necrosis with reactive inflammation and fibrosis. It was hypothesed 
that, after losing its negative feedback mechanism, the resulting elevation of 
endogenous ACTH may cause adrenal necrosis as formerly described in man. 
Sieber-Ruckstuhl et al. (66) realized that, although low aldosterone levels were 
measured after mitotane and after trilostane treatment. Dogs which were given 
mitotane regularly showed signs of aldosterone deficiency while dogs on trilostane 
treatment still appeared healthy. The authors developed the theory that steroid 
precursors accumulating due to the blockade of 3ß-hydroxysteroid dehydrogenase 
and supposedly other enzymes may also have cortisol effect.  
Wenger et al. (25) also noticed that there seems to be no correlation between serum 
concentrations of aldosterone and potassium during treatment. Thus, there has to be 
at least one other mechanism that regulates the plasma potassium concentration. A 
direct effect of trilostane is possible. In contrast to this thesis, Potts et al. (57) could 
not verify any direct or indirect hormonal activity of trilostane in rats. 
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Use in canine adrenal-dependent hyperadrenocorticism 
Trilostane has been under veterinary product licence only for the treatment of canine 
PDH and recently was also approved for the treatment of AT. Although 15 to 20% of 
the cases of canine spontaneous HAC are adrenal-dependent (47), the number of 
cases described involving a cortisol secreting adrenal mass is limited. One of the 
reasons may be that the treatment of choice for AT is the surgical excision. Two of 
the studies mentioned above also dealt with the trilostane treatment of AT (41,61), 
describing a clinical outcome which was comparable to the results of the treatment 
of the dogs with PDH. In 2003, a case report about the successful treatment of a dog 
with adrenal-dependent hyperadrenocorticism was published by Eastwood et al. (15).  
The mean survival time of AT depends on the malignancy of the tumour whose 
tendency to metastasize is not influenced by trilostane. Therefore, trilostane may be 
inferior to mitotane for the prevention and control of metastatic disease (45).  
  
3. Effect of trilostane on hormones and electrolytes  
 
3a. Physiology 
 
Cortisol 
In dogs, cortisol is the most important endogenous glucocorticoid hormone. It 
increases gluconeogenesis and thus increases glucose levels through the metabolism 
of amino acids. While parts of these glucose molecules are stored in the liver, 
glucose is also released into the blood stream. Cortisol has also an antagonistic effect 
on insulin which contributes to this increase of blood glucose since glucose uptake 
into cells is decreased. Because the amino acids are transformed into carbohydrates, 
cortisol has a catabolic effect. Muscle weakness and general lethargy are the results. 
Cortisol is also lipolytic with high plasma levels of fatty acids and lipoproteins. This 
results in a redistribution of body fat (47). 
 
Cortisol causes immunosuppression, for example through inhibiting the effect of 
lymphocytes, via reducing lymphocyte cell division and antibody release (27). 
Polyuria and polydipsia are frequently found in patients with increased cortisol levels. 
Cortisol has an antagonistic effect on the antidiuretic hormone receptors in the 
collecting ducts of the kidney. Thus, the urine concentrating ability is markedly 
reduced. Furthermore cortisol prolongs the telogenic state of hair follicles, thus lost 
hair growth is reduced.  
 
Endogenous ACTH 
The secretion of ACTH is regulated by corticotropin-releasing factor (CRF), a peptide 
produced and secreted in the paraventricular nucleus of the hypothalamus. This 
nucleus in turn receives many nervous connections from the limbic system and lower 
brain stem. Initiated by physical or mental stress CRF is produced and secreted and 
it influences the release of ACTH from the anterior pituitary gland. The anterior 
pituitary gland can secrete only minute quantities of ACTH in the absence of CRF. 
ACTH stimulates the secretion of cortisol from the adrenal glands, but it also 
enhances the production of adrenal androgens. Through a negative feedback 
mechanism, high amounts of cortisol in the blood stream inhibit further secretion of 
ACTH by inhibiting the hypothalamus to produce CRF and at the same time inhibit 
the pituitary gland to produce ACTH (25). 
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ACTH partially influences plasma aldosterone levels. Small amounts of ACTH are 
required for aldosterone secretion, providing a permissive role that allows the other, 
more important factors like potassium and angiotensin to exert their more powerful 
controls (25). 
 
Endogenous ACTH is increased or decreased, depending on the cause of HAC. In 
PDH excessive ACTH from an autonomic producing tumour stimulates both adrenal 
glands to produce excessive amounts of cortisol. As a result the adrenal glands 
become hyperplastic. In contrast, a cortisol-producing tumour of one adrenal gland 
leads to atrophy of the contralateral organ since the negative feedback mechanism 
results in almost absent plasma ACTH concentration (25,47).  
 
Figure 2: 
The hypothalamus-pituitary gland-adrenal gland axis. 
CRH (Corticotropin releasing hormone) leads to the release of ACTH (adrenocorticotropic 
hormone) which causes the release of cortisol. High cortisol levels have a negative feedback 
on CRH and ACTH release (27). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Renin and aldosterone 
Renin is an enzyme produced from prorenin in the cells of the glomerular afferent 
arterioles of the kidneys. These cells act as miniature pressure transducers that 
sense renal perfusion pressure. The most important stimulus for the release of renin 
comes from the sympathetic, ß1-adrenergic innervation of the cells of the glomerular 
afferent arterioles. The release of renin is also controlled by humoral factors such as 
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potassium, angiotensin II and atrial natriuretic peptide. Renin catalyses the formation 
of the decapeptide angiotensin I from angiotensiogen; angiotensin I is further 
converted through angiotensin converting enzyme into the octapeptide angiotensin 
II. Angiotensin II has direct vasoconstrictory effects and induces the secretion of 
aldosterone (25). 
The plasma renin level is an accepted index to assess the renin-angiotensin system 
because it is difficult to measure other components (for example angiotensin II) 
because they are not stabile and diagnostic tests are not commonly available (32). 
 
Aldosterone is a potent mineralcorticoid with two important actions: it regulates 
extracellular fluid volume and it is a major determinant of potassium homeostasis. 
Aldosterone acts predominantly on the distal convoluted tubule where it increases 
the reabsorption of sodium and the excretion of potassium. 
Four mechanisms are known to influence the secretion of aldosterone (25): The 
potassium concentration and the renin-angiotensin-aldosterone-system play the 
greatest role; serum sodium levels and ACTH-secretion have minor influences. A very 
low percentage change in potassium concentration can cause a several-fold change 
in aldosterone secretion. Thus, aldosterone activates the secretion of potassium and 
the reabsorption of sodium. 
The renin-angiotensin-aldosterone-system is activated in response to diminished 
blood flow to the kidneys as well as other stimuli (25). 
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Javadi et al. (32) have measured plasma aldosterone concentration and plasma renin 
activity in healthy dogs and in dogs with untreated HAC. Surprisingly, they found that 
chronically increased ACTH levels lead to a marked reduction of aldosterone levels. A 
decrease in aldosterone was already described by Golden et al. (20) in 1988; in 
addition, after stimulation with ACTH, they found increased levels similar to the 
concentrations of healthy dogs. Basal aldosterone levels are significantly lower in 
dogs with PDH than in healthy dogs; basal aldosterone concentrations in dogs with 
AT are significantly higher than in dogs with PDH (32). The authors speculate that 
persistent ACTH excess may cause aldosterone-secreting cells to change into 
cortisol-secreting cells. After administration of dexamethasone (0.1mg/kg), 
aldosterone concentrations decreased significantly to about 60% of the initial values 
in healthy dogs but no change is seen in dogs with PDH or AT. 
ACTH has a direct role in regulating aldosterone release under physiological 
conditions. This seems not to be true in dogs with PDH, because the 
dexamethasone-induced decrease in plasma ACTH concentrations was not associated 
with any change in aldosterone concentrations (32). 
 
The plasma levels of renin are similar in healthy dogs, dogs with PDH and dogs with 
AT (32). In dogs with PDH, renin activity increases significantly after administration 
of dexamethasone (0.1mg/kg). In dogs with AT, on the other hand, there is a 
noticeable, albeit non-significant increase of renin after dexamethasone (32). There 
are no differences in sodium and potassium levels between healthy dogs and dogs 
with HAC (32). The authors conclude that dexamethasone has two counteracting 
effects in dogs with PDH. On one hand it causes an increase in renin activity, while 
on the other hand it leads to a moderate decrease in circulating ACTH levels. Thus, 
the aldosterone concentration remains unchanged (32). 
 
Serum electrolytes 
Serum sodium and potassium levels are mainly regulated by the renin-angiotensin-
aldosterone system. Sodium is the major electrolyte of the extracellular 
compartment. Aldosterone causes reabsorption of sodium in the distal tubule of the 
kidneys (27). Amongst other variables such as urea, the permeability for sodium, 
chloride and water in the collecting tubules is regulated by the osmolal gradient of 
the kidneys and by anti-diuretic hormone. In contrast to aldosterone, atrial 
natriuretic peptide causes an increase of sodium secretion in the kidneys. The 
pressure inside the right atrium regulates its release (27). 
Potassium is the major intracellular electrolyte. Under aldosterone influence, 
potassium is actively secreted in the distal tubule (27). 
Calcium levels are regulated by the complex hormonal influences of parathormon, 
calcitonin and vitamin D (1,25-dihydroxycholecalciferol). Aldosterone has no effect on 
serum calcium levels. It is well known that cortisol has calcium-lowering potential 
which is frequently used in the medical treatment of hypercalcaemia (47). 
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3b. Effect of trilostane  
 
Cortisol 
As stated previously, cortisol is markedly increased in both conditions: PDH and AT. 
After treatment with trilostane, cortisol is significantly reduced (5,45,61,66,71). This 
reduction is used to objectivate therapy success by measuring basal and post-ACTH 
cortisol levels.  
Trilostane’s inhibitory effect on cortisol concentration lasts about 12 hours in dogs 
with PDH, while the clinical effect seems to last longer (45). This is surprising since 
trilostane plasma levels in healthy dogs peak after 1,5 hours and decrease quite 
rapidly thereafter (Arnolds, data on-file). Nonetheless clinical experience dictates that 
in most cases trilostane application once daily is sufficient (5,45,61). 
 
Treatment with mitotane results quite commonly in Addison’s disease (55). 
Interestingly, despite basal and post ACTH cortisol concentrations below 25 nmol/l, 
clinical signs of adrenocortical insufficiency are very infrequently seen in dogs treated 
with trilostane (61). It is speculated that steroid precursors that have accumulated as 
a result of enzyme inhibition have certain glucocorticoid-like effects (66). 
 
Endogenous ACTH 
Endogenous ACTH plasma levels are significantly elevated in dogs with PDH following 
trilostane therapy compared to pre-treatment values (74). Furthermore, there is a 
negative correlation between the drug-dosing interval and the ACTH concentration, 
with higher ACTH levels seen in dogs which had received trilostane more recently 
(74). The authors suggest that concurrent reduction in serum cortisol concentrations 
may result in higher levels of endogenous ACTH, following the removal of the 
negative feedback mechanism of high cortisol levels. A recently published study by 
Sieber-Ruckstuhl et al. (66) has confirmed these findings. 
 
Renin and aldosterone 
In dogs with HAC undergoing treatment with trilostane, aldosterone is less influenced 
by trilostane than cortisol. Wenger et al. (71) have measured basal cortisol, basal 
aldosterone levels and cortisol and aldosterone concentrations after stimulation with 
ACTH. Samples were taken before and 1, 4, 8 and 12 weeks after initiation of 
trilostane treatment. No significant changes in basal aldosterone levels were found 
while serum cortisol was significantly more reduced than aldosterone after 
stimulation with ACTH. Only recently, a significant increase in basal aldosterone 
levels after trilostane therapy was found with decreased post-stimulation aldosterone 
levels (66). 
 
Although there is data available on plasma renin activity in healthy dogs and dogs 
with HAC (32), no study has yet been done to evaluate the renin activity in dogs with 
HAC undergoing trilostane therapy. 
 
Serum electrolytes 
In two studies, serum sodium levels were measured. While 6 of 11 dogs were 
hypernatriaemic before the onset of therapy, only two dogs showed sodium levels 
above the normal range at the fifth re-evaluation (61). Potassium levels above the 
reference range were found in 6 of 11 dogs while none of them was hypokaleamic. 
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In another study (41), sodium levels decreased significantly under trilostane therapy.  
In this study, two dogs had sodium/potassium-ratios of less than 24 six months after 
starting therapy with trilostane. 8 of 60 dogs had potassium levels above the normal 
range six months after starting trilostane therapy.   
Wenger et al. (71) found that median potassium concentrations increased slightly 
under trilostane therapy. They found no correlation between serum potassium and 
aldosterone levels.  
So far, calcium levels have not been measured under trilostane influence. 
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IV. Hypotheses 
 
 After trilostane application, ketotrilostane is formed rapidly. Both trilostane and 
ketotrilostane are present in a state of equilibrium and circulate in the blood 
only for 10 to 18 hours after application. 
 
 Cortisol levels are reduced significantly by trilostane; the maximum effect is 
reached after 3-4 hours. Decreased cortisol is noticed longer than trilostane 
and ketotrilostane are measured in the blood stream. 
 
 In comparison to the levels before the initiation of therapy, ACTH levels are 
significantly increased after therapy with trilostane. During the day, maximum 
ACTH levels are expected when cortisol levels are at their trough level which 
will be 3 to 4 hours after trilostane uptake. 
 
 In doses routinely used for the treatment of canine HAC, trilostane does not 
decrease the aldosterone concentrations to levels that may cause symptoms of 
a live-threatening hypoadrenocortic crisis 
 
 Because there are only mild changes in aldosterone concentrations, the renin 
concentration remains stable 24 hours after trilostane application 
 
 Because aldosterone levels remain constant, administration of trilostane does 
not change sodium and potassium levels significantly. Aldosterone and cortisol 
have only minor influence on calcium levels. Thus, no significant change of 
calcium levels is expected.  
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III. Materials and Methods 
 
1. Trial procedure 
 
This study was a prospective investigation. Its objective was to ascertain the daily 
fluctuation of once daily trilostane therapy on serum electrolytes (sodium, potassium, 
calcium), endogenous ACTH, renin, aldosterone and cortisol. Furthermore, plasma 
trilostane and ketotrilostane values were measured to ascertain the uptake and to 
investigate the pharmacologic property of this compound.  
 
Primary diagnosis 
Ten dogs diagnosed with PDH were included in the study. They had to weigh more 
than 15kg and had to be healthy with the exception of PDH and symptoms caused by 
excessive endogenous cortisol production. Dogs with AT were excluded. 
 
Dogs with clinical signs suggestive of HAC were further diagnosed with an ACTH 
stimulation test, and/or a low dose dexamethasone suppression test. To distinguish 
between PDH and AT an ultrasound of the adrenal glands (where possible) and 
measurement of endogenous ACTH were performed (22).  
The ACTH stimulation test and low dose dexamethasone suppression test were 
performed as described (47). Briefly, blood samples for determination of cortisol 
levels before and 1 hour after either IM or IV injection of 0.25mg synthetic ACTH 
(Synacten®, Versatis) were collected. Cortisol concentration was measured using a 
chemiluminescence method at Biocontrol Laboratories, Mainz, Germany. A cortisol 
concentration > 550 mmol/l in the sample collected 1 hour after ACTH administration 
was considered suggestive of HAC. For the low dose dexamethasone suppression 
test, blood samples were collected before and 4 and 8 hours after IV injection of 
0.01 mg/kg dexamethasone. A cortisol concentration of >38.6mmol/l in the sample 
collected 8 hours after dexamethasone administration was considered to reflect a 
lack of suppression and was suggestive of HAC. If the cortisol concentration at 4 
hours after dexamethasone administration was <38.6mmol/l or less than 50% of the 
baseline cortisol concentration PDH was confirmed. 
Endogenous ACTH was measured from pre-analytically stabilized blood (stabilizer 
tubes containing a mixture of two protease inhibitors) using a two-site-
chemoluminometric assay at Alomed Laboratories (), Radolfzell (63).  
Included were patients with at least one positive screening test results (ACTH 
stimulation test, low dose dexamethasone suppression test) and a safe discrimination 
into pituitary-dependence. 
Adrenal ultrasound was performed at the Small Animal Clinic, Justus-Liebig-
University, Gießen, Germany. Although the whole abdomen was visualized, the major 
focus was on the adrenal glands whose minimal and maximal size was measured as 
described previously (3,24).  
 
Before treatment with trilostane, a blood sample for haematology and biochemistry 
was taken. All haematological and biochemical tests were performed at the central 
laboratory of the Small Animal Clinic, Justus-Liebig-University, Gießen. If available, a 
urine sample obtained by cystocenthesis was examined (urine dipstick, sediment and 
bacteriological examination). Dogs with positive urine culture were treated with 
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amoxicilline and clavulanic acid (20-25 mg/kg twice daily) for 2-3 weeks unless 
bacteria were found to be resistant. 
 
Control after 10 days of therapy 
After ten days of treatment, the owners were asked about their dogs’ well being, 
amount of drinking and eating, frequency and quantity of urination and changes in 
agility and skin or hair condition. Possible side effects were also questioned. The 
dogs were then re-evaluated  clinically and an ACTH stimulation test was performed. 
Post-ACTH stimulation test cortisol levels were aimed at less than 250 nmol/l. If 
cortisol levels were above 250 nmol/l or if the dog was clinically not well controlled, 
the trilostane dose was increased by 60 mg. Levels below 50 nmol/l were considered 
too low and the trilostane dose was reduced. If the dog showed adverse effects 
(lethargy, diarrhoea or vomiting), the drug was withdrawn and re-instituted after a 
few days at half the previous dose. A re-examination after 10 days was again 
performed in those dogs in which a change in the trilostane dose was needed.  
 
Control after 30 days of therapy 
Twenty days after the final dose change, the dogs were hospitalised for 36 hours and 
one day prior to blood sampling, a central venous catheter was inserted either into a 
jugular vein or into a femoral vein. Trilostane was administered the next morning at 
7 o’clock (range 6:30 to 7:30 a.m.) with food. During that day, blood samples were 
taken at the following time points: -30, 0, 15, 30, 60, 90, 120, 180, 240 minutes, 6, 
8, 12, 16, 20 and 24 hours post trilostane administration. An ACTH stimulation test 
was performed one day later, 3 to 4 hours after trilostane administration in the 
morning. 
 
Blood was taken from the central venous catheter. The first 10ml of blood were 
dismissed, then 1,2ml of blood were put into each of the following tubes: EDTA 
tubes were used for measurement of ACTH and renin, heparin tubes for serum 
electrolytes, trilostane and ketotrilostane and tubes without additive for cortisol and 
aldosterone. After taking blood, heparinized sodium chloride solution was given into 
the central venous catheter. Next, serum electrolytes were measured immediately 
from whole blood. In the meantime, the other blood samples were centrifuged and 
separated immediately. The samples were stored at -80°C. Samples were shipped in 
two instalments on dry ice to the laboratories with over-night courier. Renin, ACTH, 
cortisol and aldosterone were measured at Cambridge Specialist Laboratories (), 
Wallsend, UK while trilostane and ketotrilostane were measured at HFL Ltd. (), 
Fordham, UK. 
 
2. Treatment regiment 
 
After a final diagnosis, written consent was obtained from the owners and the dogs 
were given the following dose of trilostane: 
 
                          Weight (kg)                              starting dose 
                             < 20                                   60mg once daily 
                            20 - 40                               120mg once daily 
                             > 40                                 180mg once daily 
 
 24
3. Laboratory evaluation 
 
Trilostane and ketotrilostane 
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) bioanalytical assay 
for the measurement of trilostane and ketotrilostane has been developed and 
validated over the concentration range 5 – 1000 ng/ml in canine plasma (38) 
Trilostane and ketotrilostane were extracted from plasma using a solid phase 
extraction procedure. Chromatography was carried out using a reversed phase 
analytical column with an isocratic mobile phase. The analytes and internal standard 
were ionised using the TurbolonSpray interface on a Sciex 3000 instrument 
operating in negative ion mode. 
Trilostane and ketotrilostane are stable in canine plasma for at least 20 months. The 
assay was robust, sensitive, and highly specific. No significant matrix interference 
was observed. 
 
Cortisol 
To measure serum cortisol levels, a radioimmunoassay (RIA) was used. It has been 
validated over the concentration range 20 – 1656 nmol/l. Normal dogs show serum 
cortisol levels up to 250 nmol/l. 
 
ACTH 
An immunoradiometric assay (IRMA) was used to measure endogenous ACTH out of 
EDTA plasma. A sandwich assay with solid-phase bead system was performed. The 
test has been validated over the concentration range 5.0 – 600 pg/ml. The reference 
range for normal dogs lies between 20 and 80 pg/ml (22). 
 
Aldosterone 
For serum aldosterone measurement, a radioimmunoassay (RIA) was performed, 
with solid phase coated tube separation (coat-a-count aldosterone). The sensitivity 
lies at 20 pmol/l, the upper limit is 3300 pmol/l. Reference range in normal dogs is 
up to 960 pmol/l (54).  
 
Renin 
Renin was measured using a radioimmunoassay (RIA), again with solid-phase coated 
tube separation (gammacoat plasma renin). The assay has been validated over the 
range 0.08 – 5.0 ng/tube. Reference range in normal dogs ranges from 0.22 – 2.4 
ng/ml/hr (54,68).  
 
Serum electrolytes 
Serum electrolytes were measured with an ion-selective electrode system (AVL, 
Roche), which has been used extensively in veterinary medicine. Reference ranges in 
normal dogs for sodium are 141 – 152 mmol/l, for potassium are 3,6 to 5,4 mmol/l 
and for ionized calcium are 1,2 and 1,45 mmol/l. 
  
4. Data Analysis 
 
Normality of the data was analysed by the Shapiro-Wilk test. Logarithmic 
transformation was performed of data which were not distributed normally. An 
analysis of variance (ANOVA) with repeated measures (time) was performed for 
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transformed and non-transformed data. To assess at which time point a statistical 
change in comparison with the initial value could be seen, a Dunnett-test was used. 
The Friedman’s test was used for data which were not normally distributed even 
after logarithmic transformation. Here pair-wise comparison between time-points and 
baseline was done by Wilcoxon-Wilcox. For statistical analysis, data points below the 
detection limit of the assay were given a number of the arithmetic mean between the 
lower assay level and zero. A P-value of ≤ 0.05 was considered significant. 
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V. Results 
 
1. Baseline results 
 
Ten dogs with PDH fulfilled the inclusion criteria and could be recruited for this study 
(for patient data see table 1). The mean (± SD) age and weight of the dogs were 9.3 
± 0.67 years and 31.9 ± 6.4 kg, respectively. The starting dose of trilostane ranged 
from 60mg to 180mg once daily with a mean of 4.2 ± 0.55mg/kg. Since all dogs 
were well adjusted on the 10th day of therapy, no changes of the dose were 
necessary. 
  
Table 1:  Signalement of dogs included in this study with trilostane dose used for 
treatment of pituitary-dependent  hyperadrenocorticism. 
PATIENT BREED SEX AGE (y) WEIGHT 
(kg) 
TRILOSTANE 
DOSE (mg) 
TRILOSTANE 
DOSE 
(mg/kg) 
 
Dog 1 
 
Irish Setter  
       m 
 
       9 
 
      27 
 
       120 
 
4.44 
 
Dog 2 
 
German Short 
Hair 
 
      (m) 
 
       9 
 
      40 
 
       180 
 
4.50 
 
Dog 3 
 
Mixed breed  
      (f) 
 
      13 
 
    15,5 
 
        60 
 
3.87 
 
Dog 4 
 
Münsterländer  
       f 
 
       9 
 
      28 
 
       120 
 
4.29 
 
Dog 5 
 
Pointer  
       m 
 
       8 
 
      36 
  
       120 
 
3.33 
 
Dog 6 
 
Dalmatian  
      (m) 
 
      10 
 
      27 
 
       120 
 
4.44 
 
Dog 7 
 
Staffordshire 
Bullterrier 
 
       (f) 
 
       9 
 
      32 
 
       120 
 
3.75 
 
Dog 8 
 
Collie  
       m 
 
       9 
 
      42 
 
       180 
 
4.29 
 
Dog 9 
 
Golden 
Retriever 
 
       (f) 
 
      10 
 
      32 
 
       120 
 
3.75 
 
Dog 10 
 
Beagle  
       (f) 
 
      11 
 
      23 
 
       120 
 
5.22 
 
Legend: m = male; f = female; () = neutered/spayed 
            Trilostane dose: all doses given once daily 
 27
The dogs were presented to a veterinarian because of varying symptoms. Nine of the 
ten dogs were presented due to polyuria, polydipsia and/or nocturia. The owners of 
four of the dogs described a general weakness and difficulty to walk. Four dogs 
showed focal alopecia and signs of superficial pyoderma. Two dogs were presented 
because of excessive panting. One dog’s owner did not notice polyuria/polydipsia 
(dog 10); this owner was concerned because of his dog’s immense appetite and 
increasing weight. 
The haematology and biochemistry results of all dogs before and 30 days after the 
onset of therapy are shown in table 3. 
 
2. Clinical Improvement 
 
Control after 10 days of therapy 
After 10 days of therapy (range: day 9 to day 12), all patients had clinically 
improved. According to the owners, all but one dog (dog 9) showed a noticeable 
decrease of thirst and the quantity and frequency of urination diminished. Panting 
improved in two of two dogs (dogs 6 and 10) and all but one (dog 9) seemed to be 
more agile and generally feeling better. None of the dogs showed adverse effects. 
The girth and weight did not decrease in any of the dogs and all were still 
polyphagic. The skin condition of the patients with skin or hair problems (dogs 1, 4, 
5 and 9) had not improved visibly. 
 
An ACTH stimulation test was performed on every dog on the tenth day of therapy, 3 
to 4 hours after trilostane administration in the morning. All dogs showed a 
significant reduction in post-ACTH cortisol levels (table 2). 
  
Control after 30 days of therapy 
Second re-examination happened on the 30th day of therapy (range: day 28 to day 
35). All dogs were hospitalized and blood samples were taken at fixed time points. All 
owners but one (dog 9) reported improvement in clinical well-being. Although skin 
conditions had only improved slightly, hair started to re-grow in dogs with 
dermatological problems. None of the patients showed adverse effects and all but 
one dog (dog 9) seemed more agile than before treatment. 
 
Haematology and biochemistry results had generally improved although not all were 
within normal limits (table 3 + 4). 
  
Cortisol values pre and post ACTH stimulation test remained similar to the 10 day re-
evaluation (figure 4, table 2) and the trilostane dose was maintained the same in all 
dogs. 
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Table 2: Results of ACTH stimulation test before and after onset of therapy with 
trilostane.  
Before the onset of therapy, not all of the ACTH stimulation tests showed positive results; in 
these cases, hyperadrenocorticism was confirmed by other diagnostic tests. After 10 and 30 
days of therapy, all patients’ ACTH stimulation tests showed improved results.  
 BEFORE THERAPY 10TH DAY OF 
THERAPY 
30TH DAY OF 
THERAPY  
 Cortisol 
0 hr 
(nmol/l) 
Cortisol 
1 hr 
(nmol/l) 
Cortisol 
0 hr 
(nmol/l) 
Cortisol 
1 hr 
(nmol/l) 
Cortisol 
0 hr 
(nmol/l) 
Cortisol 
1 hr 
(nmol/l) 
Dog 1 193.13 595.94 77.25 63.46 115.88 154.50 
Dog 2 80.01 397.30* 46.90 68.80 27.59 85.53 
Dog 3 148.99 474.55* 16.55 41.39 60.70 80.01 
Dog 4 118.64 653.88 63.46 115.88 35.87 135.19 
Dog 5 129.67 471.79* 60.70 104.84 24.83 46.90 
Dog 6 184.85 488.34* 33.11 74.49 19.31 132.43 
Dog 7 209.68 830.46 22.07 102.08 13.80 44.14 
Dog 8 171.06 565.60 30.35 35.87 44.14 60.70 
Dog 9 107.60 618.02 35.87 37.95 < 13.80 38.63 
Dog 10 148.99 811.15 77.25 124.16 35.87 118.64 
Mean 
± SD 
149.26 
±41.06 
590.70 
±144.14 
46.35° 
±22.18 
76.89° 
±33.13 
39.18° 
±30.58 
89.67° 
±42.69 
 
Legend:  
 
* = ACTH stimulation test result not clearly positive; diagnosis was confirmed by low dose 
dexamethasone suppression test 
 
° = significant decrease to pre-treatment values 
 
SD = standard deviation 
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Figure 4: Serum cortisol levels 1 hour after ACTH administration (day 0, 10 and 
30 after start of trilostane treatment) in dogs treated with trilostane.  
There was a significant reduction in both 10 and 30 days’ cortisol levels with all dogs 
reaching the aimed level. 
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Table 3: Blood haematology results before and 30 days after onset of trilostane 
therapy. 
 
Legend: 
 
° = Results below the reference range 
* = Results above the reference range 
 
 
 NEUTRO-
PHILS 
(109/L) 
LYMPHO-
CYTES 
(109/L) 
EOSINO-
PHILS 
(109/L) 
RED BLOOD 
CELLS 
(10¹²/L) 
 
PLATELETS 
(109/L) 
 Day   
0 
Day 
30 
Day   
0 
Day 
30 
Day   
0 
Day 
30 
Day   
0 
Day 
30 
Day    
0 
Day 
30 
Dog 
1 
 
5.54 
 
 
8.73 
 
0.67° 
 
2.90 
 
0.07 
 
0.75 
 
5.96 
 
5.98 
 
696* 
 
550* 
 
Dog 
2 
 
4.17 
 
6.09 
 
0.90° 
 
1.25 
 
0.17 
 
0.18 
 
7.12 
 
6.61 
 
362 
 
364 
 
Dog 
3 
 
8.95 
 
6.18 
 
1.00 
 
1.04 
 
0.07 
 
0.06 
 
6.43 
 
5.90 
 
678* 
 
530* 
 
Dog 
4 
 
5.29 
 
6.89 
 
0.74° 
 
1.46 
 
0.07 
 
0.28 
 
8.06 
 
7.72 
 
433 
 
333 
 
Dog 
5 
 
6.56 
 
8.96 
 
1,35 
 
1.56 
 
 
0.09 
 
0.21 
 
 
7.00 
 
7.74 
 
 
445 
 
217 
 
 
Dog 
6 
 
10.03 
 
6.51 
 
0.91° 
 
0.55° 
 
0.00 
 
0.12 
 
7.8 
 
8.53* 
 
981* 
 
787* 
 
Dog 
7 
 
10.83 
 
5.28 
 
0.92° 
 
1.64 
 
0.06 
 
0.63 
 
6.17 
 
5.90 
 
634* 
 
463 
 
Dog 
8 
 
12.1* 
 
6.34 
 
0.97° 
 
1.08 
 
0.02 
 
0.16 
 
7.21 
 
7.52 
 
465 
 
239 
 
Dog 
9 
 
9.97 
 
8.23 
 
0.95° 
 
1.03 
 
0.02 
 
0.09 
 
7.21 
 
7.05 
 
382 
 
388 
 
Dog 
10 
 
10.04 
 
9.27 
 
0.87° 
 
1.11 
 
0.16 
 
0.13 
 
8.14 
 
7.98 
 
494 
 
399 
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Table 4: Some biochemistry parameters before and 30 days after onset of 
trilostane therapy. 
ALP, ALT, GLDH and cholesterol levels have decreased significantly while serum osmolality 
levels only decreased slightly. 
 ALP 
 (U/l)  
ALT 
(U/l) 
GLDH 
(U/l) 
Cholesterol 
(mmol/l) 
Osmolality 
(mmol/kg) 
 Day   0 Day 30 Day   
0 
Day 
30 
Day   0 Day 
30 
Day   
0 
Day  
30 
Day  
0 
Day 
30 
Dog 1 2710* 510* 122* 25 25.2* 1.0 6.1 4.38 315* 329* 
Dog 2 2171* 570* 48 74* 12.9* 19.1* 10.0* 7.7*   n.d.   n.d. 
Dog 3 593* 514* 52 43 15.7* 9.9 9.6* 7.1* 332* 313 
Dog 4 1023* 654* 205* 120* 30.1* 26.5* 6.9 5.7   n.d. n.d. 
Dog 5 156* 118* 33 32 15.2* 9.6 14.0* 8.10* 326* 312 
Dog 6 4470* 3765* 205* 39 40.4* 22.0* 6.6 7.02*  n.d. 325* 
Dog 7 3765* 2240* 151* 50 39.0* 11.0 4.8 5.18 325* 317* 
Dog 8 1824* 1700* 112* 113*  n.d. 28.0* 10.4* 6.76  n.d. 310 
Dog 9 1986* 1535* 158* 141* 17.0* 4.0 7.1* 8.11* 364* 285° 
Dog 10 1265* 958* 116* 68* 17.9* 10.5 9.6* 7.18* 334* 315* 
mean 
± SD 
1996.3 
±1360.3 
1375.4 
±1072.9 
120.2 
±61.7 
70.5 
±40.8 
23.7 
±10.5 
14.2 
±9.2 
8.5 
±2.7 
6.7 
±1.3 
332.7 
±16.7 
313.3 
±13.2 
 
Legend: 
 
° =  Results below the normal range 
* =  Results above the normal range 
n.d.= not done 
ALP = alkaline phosphatase 
ALT = alanine amino transferase 
GLDH = glutamate dehydrogenase 
SD = standard deviation 
 
Complications 
Dog 3 showed good clinical improvement upon therapy and was clinically well 
controlled after 10 and 30 days. Shortly before administration of trilostane during the 
hospitalisation period (day 31) the dog collapsed unexpectedly. After two minutes of 
unconsciousness, the animal was able to rise but was still depressed. Complete blood 
examination and thoracic radiographs did not reveal anything abnormal and the dog 
made an uneventful recovery. This dog was removed from the study as electrolyte 
and hormone parameters might be affected by this collapse.  
 
Dog 9 still showed polyuria and polydipsia on its 10 and 30 day re-examination. 
However, the post-ACTH cortisol levels had normalised and complete blood 
examination revealed a decrease in ALP-levels. Furthermore serum osmolality was 
within normal limits indicating that there might be more likely primary polydipsia with 
compensatory polyuria. Additionally, the dog had great difficulty in raising or going 
up the stairs. It had a history of arthrosis in both knees and hips for many years and 
had undergone surgery because of a ruptured cruciate ligament unilaterally two 
years previously. Treatment with non-steroidal anti-inflammatory drugs was 
recommended and the dog showed improvement in its agility. 
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3. Plasma trilostane and ketotrilostane levels 
 
In all but dog 7, maximal trilostane plasma levels were reached after a 1.5 to 3 
hours. After reaching maximal concentration, mean trilostane plasma levels 
decreased rapidly and became undetectable 12 hours after trilostane administration. 
There was a significant increase of plasma trilostane levels between 1 and 4 hours 
post dosing (P< 0.05) (figure 5). 
With the exception of dog 7, all dogs showed the same trilostane plasma curve, 
although the maximum concentration varied widely (dog 1: maximum levels of 2206 
ng/ml; dog 5: maximum levels of 233 ng/ml).  
 
Ketotrilostane plasma levels also peaked after 1.5 to 3 hours in all but one dog (dog 
7). A significant increase of plasma ketotrilostane levels was seen between 1.5 and 4 
hours post dosing (p < 0.05). After that, mean ketotrilostane plasma levels 
decreased rapidly (figure 6). Basically 12 hours after trilostane intake, ketotrilostane 
plasma levels were below the detection limit of the assay. 
 
Figure 5: Mean serum trilostane levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane. 
The non parametric data were initially logarithmized and mean and standard deviation of 
these values were calculated. For graphic display these results were delogarithmized again. 
Positive whiskers indicate geometric mean times variance while negative whiskers show 
geometric mean devided by variance. Asterices show significant changes from postdosing 
levels.  
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Figure 6: Mean serum ketotrilostane levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
For explanation of graphical display see figure 5. 
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Figure 7: Mean trilostane and ketotrilostane levels in 8 dogs with pituitary-
dependent  hyperadrenocorticism on day 30 of treatment with trilostane.  
Comparison of mean trilostane/ketotrilostane 
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Trilostane and ketotrilostane plasma curves of dog 7 differ markedly from the other 
dogs (figure 8 and 9). While all the other dogs had one peak concentration, the 
plasma levels of trilostane and ketotrilostane peaked at 1, 4 and 16 hours after drug 
application. Interestingly, 30 minutes before trilostane application, which corresponds 
to 23½ hours after last day’s trilostane application, neither trilostane nor 
ketotrilostane were detectable.  
 
 
 
 
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Figure 8: Serum trilostane and ketotrilostane levels of dog 7 on day 30 of 
treatment with trilostane. 
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The ratio of trilostane to ketotrilostane indicates that shortly after drug 
administration most trilostane is not yet converted to ketotrilostane, however over 
the next 16 hours, the ratio gradually decreases as more and more trilostane is 
converted to ketotrilostane (figure 9). 
 
Figure 9: Ratio of serum trilostane to serum ketotrilostane in 8 dogs with 
pituitary-dependent  hyperadrenocorticism on day 30 of treatment with trilostane 
(all dogs except of dog 7). 
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4. Cortisol 
 
Mean serum cortisol levels decreased significantly after trilostane dosing (P < 0.001). 
Pair wise comparison between baseline value and time points showed a significant 
decrease between 2 and 4 hours (P < 0.05) post drug administration (figure 10). In 
six dogs, the lowest cortisol concentration was below the detection limit of the assay 
at least once during the day. No adverse clinical effects were seen in any of the dogs 
at those time points. 
 
Figure 10: Mean serum cortisol levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
For explanation of graphical display see figure 5.  
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5. endogenous ACTH 
 
Mean endogenous ACTH plasma levels increased significantly after trilostane 
application (P < 0.001). By Dunnetts comparison, a significant peak was reached 
between 3 to 12 hours (figure 11) post dosing. After 12 hours mean levels decreased 
back to baseline levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
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Figure 11: Mean plasma levels of endogenous ACTH in 8 dogs with pituitary-
dependent  hyperadrenocorticism on day 30 of treatment with trilostane.  
For explanation of graphical display see figure 5.  
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Comparison of endogenous ACTH and cortisol levels 
While serum cortisol levels decreased with minimum levels 3 hours after drug dosing, 
endogenous ACTH increased after trilostane application and reached a peak level 
after 4 to 8 hours (figure 12).  
 
Figure 12: Comparison of serum cortisol and plasma endogenous ACTH levels. 
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legend: 
ACTH  =  Adrenocorticotropic hormone
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6. Aldosterone 
 
In the first hours after trilostane application serum aldosterone levels remained more 
or less the same in all dogs (figure 13). There was a significant increase in mean 
serum aldosterone concentration between 16 and 20 hours (P<0.01). In two dogs, 
serum aldosterone levels were below the detection limit of the assay on a few time 
points throughout the day, however no adverse effects at these time points were 
seen. 
 
Figure 13: Mean serum aldosterone levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
For explanation of graphical display see figure 5.   
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7. Renin 
 
Renin plasma activity levels increased significantly after trilostane application (P = 
0.0002) and reached peak levels after 8 hours (figure 14). While staying at a stable 
level for the next 12 hours, renin plasma activity levels decreased slightly 20 hours 
after trilostane dosing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
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Figure 14: Mean plasma renin activity levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
For explanation of graphical display see figure 5.  
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8. Electrolytes 
 
Sodium 
Plasma sodium levels remained within the reference range (141–152 mmol/l) 
throughout the day in all but 4 dogs. Dogs 4, 5, 8 and 10 had short episodes each of 
mild hypernatraemia shortly before or after trilostane application. No episode of 
hyponatraemia was seen in any of the dogs. Throughout the study period there was 
only mild fluctuation of mean serum sodium concentration (figure 15) (P = 0.582), 
however, there was quite a marked inter-individual variation. 
 
Figure 15: Mean serum sodium levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
Since data were normally distributed graphical display shows mean results ± standard 
deviation 
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Potassium 
There was a significant decrease of mean plasma potassium concentration (figure 
16) between 0,5 and 2 hours after trilostane administration (P < 0.05). Two dogs 
had one or two mild episodes of plasma potassium levels above the reference range 
(3,6 – 5,4 mmol/l) and no dogs became hypokalaemic. 
 
Figure 16: Mean serum potassium levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
Since data were normally distributed graphical display shows mean results ± standard 
deviation. 
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Sodium/Potassium-ratio 
Although three dogs showed sodium/potassium-ratios below 27 at varying time 
points after trilostane application (table 5), none showed any adverse effects. 
 
Table 5: Sodium/potassium-ratio in 8 dogs with pituitary-dependent  hyperadrenocorticism 
on day 30 of treatment with trilostane. 
A sodium/potassium ratio of less than 27 was considered a high risk of causing signs of 
hypoadrenocorticism. Results below this level are written in bold. 
TIME 
POINTS 
(hours) 
 
-0.5 
 
0 
 
 
0.25 
 
 
0.5 
 
1 
 
1.5 
 
2 
 
3 
Dog 1 25.1 23.9 33.1 34.3 34.3 34.4 32.9 32.9 
Dog 2 33.5 30.2 32.4 32.4 31.3 30.9 30.4 31.3 
Dog 4 26.7 32.5 30.2 31.0 34.3 31.7 32.8 31.7 
Dog 5 34.0 32.1 33.0 32.1 30.8 31.5 32.4 33.6 
Dog 6 30.0 32.0 30.0 32.6 30.2 32.8 32.1 28.1 
Dog 7 29.0 40.0 32.7 31.0 33.3 32.0 34.9 32.9 
Dog 8 32.0 32.2 36.3 39.2 38.7 38.5 37.7 35.1 
Dog 9 30.2 32.3 32.3 30.4 33.8 33.8 33.8 33.3 
Dog 10 29.8 30.0 30.0 31.2 31.7 32.3 34.2 29.4 
 
   
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TIME 
POINTS 
(hours) 
 
4 
 
6 
 
 
8 
 
 
12 
 
16 
 
20 
 
24 
Dog 1 31.4 32.7 30.4 28.5 27.7 29.6 29.6 
Dog 2 29.5 26.5 29.8 28.4 31.5 30.9 30.9 
Dog 4 32.0 29.6 29.0 31.4 28.3 30.2 28.3 
Dog 5 33.1 32.4 29.4 29.6 31.5 28.8 30.8 
Dog 6 32.1 33.6 29.6 29.6 29.8 31.7 30.6 
Dog 7 30.4 30.2 29.2 31.7 28.1 29.1 28.9 
Dog 8 36.7 36.4 35.1 34.8 32.6 32.8 31.9 
Dog 9 31.8 30.9 27.7 28.4 31.1 31.1 27.4 
Dog 10 29.3 28.7 33.0 27.6 31.7 31.7 31.2 
  
Potassium/Aldosterone-ratio 
While mean plasma potassium levels decreased during the first 2 hours after 
trilostane application, serum aldosterone levels increased slightly. After this time 
point, plasma potassium levels showed a slight increase back to initial levels. Serum 
aldosterone levels increased non-significantly 16 to 20 hours after trilostane dosing 
(figure 17). 
 
Figure 17: Comparison of aldosterone and potassium development in 8 dogs with pituitary-
dependent  hyperadrenocorticism on day 30 of treatment with trilostane. 
Comparison of aldosterone and potassium 
development
4
4,2
4,4
4,6
4,8
5
5,2
-0,
5
0,2
5 1 2 4 8 16 24
time (hours)
po
ta
ss
iu
m
 le
ve
l 
(m
m
ol
/l)
0
100
200
300
400
500
al
do
st
er
on
e 
le
ve
l 
(p
g/
m
l)
potassium
aldosterone
 
 
Calcium 
Mean plasma calcium levels showed a slight, however non-significant decrease (P = 
0.593) shortly after trilostane application with minimum ionized calcium levels 2 
hours after drug dosing. Throughout the study period there was only mild fluctuation 
of mean plasma calcium concentration (figure 18). Plasma calcium levels remained 
within the reference range (1,2–1,45 mmol/l) in all but one dog throughout the day. 
Dog 10 was mildly hypercalcaemic ¼ to ½ hour and again 4 hours to 24 hours after 
trilostane administration. The maximum calcium level reached 1,55mmol/l (12 hours 
after trilostane application). None of the dogs was hypocalcaemic. 
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Figure 18: Mean serum calcium levels in 8 dogs with pituitary-dependent  
hyperadrenocorticism on day 30 of treatment with trilostane.  
Since data were normally distributed graphical display shows mean results ± standard 
deviation 
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VI. Discussion 
 
The signalement of the dogs in this study is comparable to previous reports of canine 
HAC with the exception of breed (45,51,61). There was an equal sex distribution and 
similar age range, however while typical breeds are mostly small dogs such as 
poodles, terriers and dachshounds, (36,51,61) the inclusion criteria of this study 
dictated a weight of at least 15 kg. Of the breeds reported here, only golden 
retrievers and beagles are known to develop HAC regularly (47).  
 
Historic complaints and physical findings in these dogs were consistent with the 
literature (36,45,47) with nine of 10 dogs showing polyuria, polydipsia and/or 
nocturia. Although no polyuria/polydipsia was noticed in dog 10, it had a low specific 
gravity of the urine (specific gravity of 1008). 
 
Although well controlled clinically as well as based on the ACTH stimulation tests, 
dog 3 collapsed unexpectedly and seemed to be unconscious for a few minutes just 
before the blood sampling procedure on day 30. Shortly after this syncope everything 
normalised and no further abnormalities could be detected on a full investigation 
(including radiographs and echocardiography). Because of this incident, the dog was 
removed from further blood sampling. While, the exact reason of this incident 
remains unclear a possible explanation might be a thrombus formation, which 
dissolved spontaneously. Dogs with HAC are known to have a state of 
hypercoagulability which might result in thromboembolism (31). The reasons are 
higher levels of procoagulant factors (factors II, V, VII, IX, X, XII) and lower levels of 
anti-coagulative antithrombin III (31). Hypercoagulability may still happen weeks 
after starting therapy for HAC. About two years after this episode, the dog continues 
to receive trilostane, remains healthy and no syncope has happened again. 
 
Clinical improvement was good in all but one dog (dog 9) confirming the efficacy of 
trilostane for canine PDH (7,41,45,61). Dog 9 had serum cortisol concentrations 
before and after ACTH stimulation well within the normal range (13,58) but 
continued to suffer from polyuria and polydipsia. Serum osmolality was decreased, 
indicating potential hyperhydration as seen in dogs with psychogenic polydipsia (19, 
52). After water restriction, the urine specific gravity increased, demonstrating that 
the dog was able to conserve its urine concentrating potential within the kidneys. 
Polyuria in dogs with HAC can be due to abnormal ADH-receptor interaction when 
abnormally high serum cortisol levels are present. However, psychogenic polydipsia 
is also possible as part of the clinical picture. Additionally, orthopaedic problems 
worsened under trilostane therapy in dog 9. Because cortisol has an anti-
inflammatory effect (35), dogs with arthrosis and painful orthopaedic problems show 
less clinical symptoms as long as HAC is untreated. Under treatment cortisol blood 
levels decrease and so does the anti-inflammatory effect. As a result, these patients’ 
orthopaedic symptoms worsen (Neiger; personal observation). After treatment with 
non-steroidal anti-inflammatory drugs, dog 9 showed improvement in its agility.  
 
Canine HAC results in several typical haematological and biochemical abnormalities, 
such as a stress leucogram or elevated levels of alkaline phosphatase and cholesterol 
(47). Irrespective of treatment modality of HAC, several of these abnormalities 
normalise (33). Similarly, laboratory findings had generally improved on the 30th day 
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of therapy in the dogs of this study, although some of the parameters still were not 
within the reference range. 
  
In rats and monkeys trilostane absorption is quick after oral dosing with peak blood 
concentrations occurring between 0.5-1 hour (rat) and between 2-4 hours (monkey) 
(57). In human volunteers the peak concentrations are reached after 1 hour (60). 
Trilostane plasma levels in the dogs of this study with PDH confirm that trilostane 
uptake is fast and maximum levels are reached after 1.5 hours. Similar results have 
also been found in clinically healthy beagle dogs given 10 mg/kg trilostane orally and 
peak plasma trilostane levels measured at 1.5-2 hours later (Arnolds Ltd. - data on 
file). The decline of trilostane follows a triexponential decrease with trilostane cleared 
from the blood after 7 hours (rat), 6-8 hours (human) and 48 hours (monkey) 
(39,57,60). Trilostane clearance from the blood in the dogs of this study is 
comparably fast and after about 12 hours, no more trilostane is detectable. 
 
In rats ketotrilostane is rapidly formed from trilostane (39). As shown in figure 5, 
shortly after oral application of trilostane the plasma level of trilostane is much higher 
than that of ketotrilostane. However, ketotrilostane is formed rapidly and after 0.5 to 
1 hour, the ratio starts to shift towards ketotrilostane with one molecule of 
ketotrilostane formed from one molecule of trilostane. In healthy rats, McGee et al. 
(39) found that ketotrilostane is formed from trilostane until an equilibrium is 
reached. Not enough data is available to say wether an equilibrium will be obtained 
in dogs with PDH but it is clearly visible that maximum trilostane and ketotrilostane 
plasma levels are reached more or less simultaneously. The reason of  a proportional 
shifts towards ketotrilostane later in the day may be explained due to the facts that 
ketotrilostane is one of the metabolites of trilostane, as has been shown previously 
(39), or it might indicate that trilostane is secreted more rapidly than ketotrilostane.  
 
Because ketotrilostane is formed rapidly from trilostane, the peak levels of both 
compounds are seen at the same time point, 1.5 to 2 hours after drug 
administration. Although both substances contribute to the drug’s effect, 
ketotrilostane shows a 1.7 times higher activity than trilostane in the inhibition of 
steroidogenesis (38). This might explain why the time point of the lowest cortisol 
concentrations is slightly delayed.   
 
The trilostane and ketotrilostane profiles of dog 7 remain unclear. Interestingly, at 
time point -30 minutes, i.e. half an hour before trilostane was given, both trilostane 
and ketotrilostane plasma levels below the detection limit of the assays were found. 
This corresponds with plasma trilostane and ketotrilostane levels at this time point in 
all other dogs. As such it seems that the erratic profiles of dog 7 might be a single 
event. 
 
Maximum effect of trilostane on glucocorticoid production is reached 2-4 hours after 
application of the drug. Accordingly, at this time point minimal cortisol levels can be 
found (44). As a result, endogenous ACTH levels increase 4 to 8 hours after drug 
dosing because the negative feedback mechanism which also influences the tumour’s 
secretion of ACTH is removed. In comparison to healthy dogs’ reactions, the 
tumour’s answer to the lost negative feedback is exaggerated and prolonged. 
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Most interestingly, effects of trilostane on cortisol levels can be found long after 
plasma trilostane levels reach non-detectable levels. This is consistent with previous 
observations (45). No clear explanation can be given from this study but several 
mechanisms could be speculated. Firstly, it might be possible that the assays 
measure only circulating trilostane or ketotrilostane levels while other metabolites, 
which have an effect of stroidogenesis and are excreted more slowly, are not 
measured. Secondly, intracellular effects of trilostane or its metabolites on steroid 
receptor interaction (not only enzyme inhibition) are possible. Or thirdly, prolonged 
enzyme inhibition by trilostane or its metabolites must also be considered.  
 
Cortisol levels were very low in all dogs and even below the detection limit of the 
assay in most of the patients on at least one occasion (all in all, on 18 occasions), 
but none of the dogs showed any adverse effects and all appeared clinically healthy. 
 
Because of the ACTH-producing tumour, plasma ACTH-levels is higher in dogs with 
PDH than in healthy dogs (47,74). Under therapy, the negative feedback of cortisol is 
removed and the endogenous ACTH levels of these dogs increase even more. Thus, 
dogs with PDH undergoing therapy show much higher ACTH levels than healthy dogs 
or dogs with PDH where treatment has not been initiated, yet (57,66,73). The 
highest ACTH levels are found at the time point of maximum trilostane effect, 3 
hours after drug dosing. All blood samples showed endogenous ACTH levels above 
the normal range. At maximum endogenous ACTH levels, concentrations of up to 15 
times the reference range (20 – 80 pg/ml) could be found. 
 
Because there was quite marked inter-individual variation of endogenous ACTH levels 
over the 24 hours and in some dogs changes in endogenous ACTH levels were only 
minimal, measurement of endogenous ACTH is most likely not useful for the 
evaluation of therapeutical success of trilostane, as has been suggested (6). 
 
Three hours after trilostane intake, at the time point of maximum trilostane effect, 
aldosterone levels were decreased. In two of the patients, aldosterone 
concentrations lower than the detection limit of the assay were found. Because 
trilostane is an inhibitor of the 3ß-hydroxysteroid dehydrogenase, an enzyme which 
has an effect on the production of all steroid hormones in the adrenal cortex (57), 
this effect is not surprising. Although aldosterone levels are low, none of the dogs 
showed any adverse effects. 
 
After its lowest serum concentration, mean aldosterone levels increased again.  
Aldosterone levels well above the reference range were found. This is consistent with 
the results of Sieber-Ruckstuhl et al. (66) and in contrast to a study by Wenger et al. 
(71) who found aldosterone levels unaltered. On the other hand, both noticed that 
trilostane’s effect on serum aldosterone concentration is less pronounced than on 
serum cortisol concentration. Although only playing a minor role, ACTH is 
nevertheless known to influence serum aldosterone levels (25). Therefore, long-term 
excessive amounts of endogenous ACTH – as seen in dogs with PDH - may lead to 
increased serum aldosterone levels as long as the effect of trilostane does not lower 
them. 
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Eight to 20 hours after trilostane administration, renin plasma activity is significantly 
increased (8h: p < 0.01 ; 12h to 20h: p < 0.05). Since peak aldosterone 
concentrations are found 16 to 24 hours (16h: p < 0.05; 20h to 24h: p < 0.01) after 
drug dosing, renin may also have an effect on this steroid hormone. 
 
Renin plasma activity shows a fidgety profile in the first hours after trilostane uptake 
which is consistent with the maximum effect of trilostane. At this time point, 
aldosterone reaches its lowest concentration. Renin may increase because of a 
decrease of blood flow to the kidneys second to low aldosterone levels and, 
therefore, increased loss of fluids via the urine. This represents one of the two main 
mechanisms through which renin activity is regulated. The second trigger of an 
increase of renin activity is a high level of plasma potassium. Surprisingly, at the time 
point of maximum effect of trilostane, potassium levels were decreased. Thus, this 
should cause low renin activity levels. 
 
Potassium levels show a surprising development. At times when aldosterone was at 
its lowest concentration, potassium levels were low, but nevertheless well inside the 
reference range. Wenger et al. (25) have noticed recently that there seems to be no 
correlation between serum concentrations of aldosterone and potassium during 
treatment. Because aldosterone causes an active secretion of K -ions, at time points 
of low aldosterone levels, high potassium concentrations would have been expected. 
Thus, there has to be at least one other mechanism that regulates the plasma 
potassium concentration. A direct effect of trilostane is possible. Because trilostane is 
a competitive inhibitor of enzymes situated in glucocorticoid and mineralcorticoid 
biosynthesis, it may also have a partially agonistic effect. The chemical structure of 
trilostane is in parts similiar to the one of steroid hormones. Thus, trilostane may 
have a mineralcorticoid effect and it may directly cause the decrease of potassium 
levels 3-4 hours after trilostane uptake. This also is the time point when maximum 
trilostane concentrations can be found. However, Pott et al. (57) found no direct or 
indirect hormonal activity of trilostane in rats. 
 
Another hypothesis was developed recently by Sieber-Ruckstuhl et al. (66); they 
noticed that, although low aldosterone levels were measured both after mitotane as 
well as trilostane treatment, dogs which were given mitotane regularly showed signs 
of aldosterone deficiency while dogs on trilostane treatment still appeared healthy. 
The authors conclude that steroid precursors accumulate because of the blockade of 
3ß-hydroxysteroid dehydrogenase and supposedly other enzymes may also have 
mineralcorticoid effects. This seems plausible since both mitotane and trilostane use 
completely different mechanisms to decreased cortisol levels. Thus, if these 
precursors not only have cortisol, but also some mineralcorticoid effect, this may 
explain why potassium levels are low when, at the same time, aldosterone levels are 
very low, too. 
 
This potassium-lowering effect would have to be very strong: it should not only 
decrease potassium levels, but also compensate the effect of low aldosterone levels 
which by itself causes increased levels of potassium. As such, it might be that both 
mechanisms work complementarily and lead to the decrease of serum potassium.  
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If decreased aldosterone would have a significant effect, one might be able to find 
abnormally low sodium:potassium-ratios. This ration was above 27 on all but three 
occasions throughout the day. Since serum potassium levels were rather decreased 
than increased and serum sodium concentration remained stable throughout the day, 
it seems that problems pointing towards a hypoadrenocorticoid abnormality are 
uncommon in dogs with PDH on trilostane. That hypoadrenocorticoid crisis can still 
be found clinically (8,14,45) might be more likely due to an adrenal necrosis which 
can be the result from long-standing increased levels of ACTH (8) than to abnormally 
low aldosterone levels in these dogs.  
 
In summary, data obtained in this study confirms that trilostane is an effective drug 
in the treatment of canine PDH. Marked aldosterone abnormalities throughout the 
day could not be seen and serum potassium level rather decreases than increases 
shortly after trilostane administration. Some of the changes in hormones and 
electrolyte levels remain unclear, especially the long-term decrease of cortisol despite 
the short plasma levels of trilostane or ketotrilostane. Therefore, further studies are 
needed to understand the effect of trilostane better. 
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VII. Summary 
 
Ten dogs with PDH took part in this study. After confirming the diagnosis, treatment 
with once daily trilostane was started. On their 10th and 30th day of therapy, the dogs 
were controlled clinically and an ACTH stimulation test was performed 3 to 4 hours 
after trilostane dosing. On the 30th day of therapy, the dogs were hospitalized and  
over 24 hours, blood samples were taken for the measurement of trilostane, 
ketotrilostane, endogenous ACTH, cortisol, aldosterone, renin and serum electrolytes. 
On the 10th and 30th day of therapy, clinical improvement was good in all but one 
dog. Laboratory findings including the ACTH stimulation test results had generally 
improved on the 30th day of therapy, although some of the parameters still were not 
within the reference range. None of the patients showed any adverse effects. 
Nevertheless, on the 30th day of therapy, one of the dogs collapsed suddenly and, 
although regenerating quickly, was removed from further blood sampling. 
Trilostane absorption was quick and ketotrilostane was formed immediately. For both 
substances, peak concentrations were reached 1.5 to 3 (4) hours after trilostane 
administration. Accordingly, lowest serum cortisol and aldosterone levels were found 
at nearly the same time points. Although cortisol and aldosterone levels were very 
low in all dogs, none showed any adverse effects.  
Because the negative feedback mechanism caused by high cortisol levels was 
removed, all dogs showed highest endogenous ACTH levels 4 to 8 hours after 
trilostane dosing. At all time points, all dogs had endogenous ACTH levels well above 
the reference range. Because there was quite marked inter-individual variation over 
the 24 hours and in some dogs changes in endogenous ACTH levels were only 
minimal, its measurement is most likely not useful for the evaluation of therapeutical 
success of trilostane. 
Serum renin activity remained rather unchanged during the day. While changes in 
serum sodium and calcium were insignificant, serum potassium showed some 
astonishing development: At times when aldosterone was at its lowest concentration 
and high potassium levels would be expected, potassium levels were low, but 
nevertheless well inside the reference range. An aldosterone-like effect of trilostane 
or of accumulating steroid precursors seems possible, although further studies are 
necessary to verify these hypotheses. This may be one of the reasons why trilostane 
is more secure in the treatment of PDH than lysodren. 
 48
VIII. Zusammenfassung 
  
Zehn Hunde mit hypophysärem Hyperadrenokortizismus nahmen an dieser Studie 
teil. Nachdem die Diagnose gesichert wurde, begann die Therapie mit einmal täglich 
verabreichtem Trilostan. Die Hunde wurden am 10ten und 30ten Tag der Therapie 
sowohl klinisch als auch mittels ACTH-Stimulationstest (3 bis 4 Stunden nach der 
Gabe von Trilostan) kontrolliert. Am 30ten Tag der Therapie wurden die Tiere 
stationär aufgenommen und über 24 Stunden Blutproben genommen zur 
Bestimmung von Trilostan, Ketotrilostan, endogenem ACTH, Kortisol, Aldosteron, 
Renin und Serumelektrolyten. 
Am 10ten und 30ten Tag der Behandlung zeigten alle Hunde außer einem ein gutes 
klinisches Ansprechen auf die Therapie. Die Ergebnisse der Laboruntersuchungen 
inklusive der durchgeführten ACTH-Stimulationstests ergaben grundsätzlich bessere 
Werte, auch wenn nicht alle Resultate den Normbereich erreichten. Keiner der 
Patienten zeigte Nebenwirkungen. Dennoch kollabierte einer der Hunde plötzlich am 
30ten Tag der Therapie, und obwohl er sich sehr schnell wieder regenerierte, wurde 
er aus der Studie entfernt. 
Die Absorption von Trilostan geschah schnell und Ketotrilostan wurde direkt gebildet. 
Höchste Konzentrationen beider Substanzen waren 1,5 bis 3 (4) Stunden nach der 
Gabe von Trilostan nachweisbar. Entsprechend wurden die niedrigsten Werte des 
Serumkortisols und des Serumaldosterons zum annähernd gleichen Zeitpunkt 
gefunden. Obwohl die Konzentrationen des Kortisol und des Aldosterons in allen 
Hunden sehr niedrig waren, zeigte keiner der Patienten Nebenwirkungen. 
Nach Wegfall des negativen Rückkopplungsmechanismus’ durch hohe Kortisolwerte 
zeigten alle Hunde höchste Werte des endogenen ACTH 4 bis 8 Stunden nach 
Tablettengabe. Zu allen Zeitpunkten hatten alle Hunde endogene ACTH-Werte weit 
über dem Normalbereich. Da sich eine starke Variation der Werte zwischen den 
Individuen während der 24 Stunden nachweisen ließ und einige Hunde nur minimale 
Veränderungen der Konzentration des endogenen ACTH zeigten, erscheint die 
Messung des endogenen ACTH nicht nützlich zur Überprüfung des Therapieerfolges 
von Trilostan. 
Die Serumreninaktivität blieb mehr oder weniger unverändert. Während sich auch die 
Konzentrationen der Serumelektrolyte Natrium und Kalzium nicht signifikant 
veränderten, wies Kalium eine erstaunliche Entwicklung auf: Zum Zeitpunkt der 
niedrigsten Aldosteronwerte, wenn entsprechend eher erhöhte Kaliumwerte zu 
erwarten wären, fanden sich niedrige Kaliumwerte, wenn auch noch innerhalb des 
Normalbereiches. Ein Aldosteron-artiger Effekt des Trilostans oder aber der sich 
bildenden Steroidvorläufersubstanzen wäre denkbar, auch wenn diese Hypothesen 
erst durch weitere Studien bewiesen werden müssen. Dies mag (unter anderem) die 
im Vergleich zum Lysodren bessere Verträglichkeit von Trilostan erklären. 
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